Oncology
[GIOTRIF] In real-world practice, sequential afatinib followed by osimertinib is a feasible and effective therapeutic strategy for EGFR m+ NSCLC patients acquiring T790M during the period of afatinib treatment1
[GIOTRIF] Based on current real-world and clinical trial evidences, the optimal regimen maybe first-line afatinib followed by osimertinib4-
[GIOTRIF] Over 1000 published cases of patients with uncommon EGFR M+ NSCLC treated with GIOTRIF®
[GIOTRIF] A sequential approach of first-line GIOTRIF® followed by various subsequent treatments can be a feasible and appropriate treatment option for patients with EGFR M+ NSCLC from TOAST study
6.28
비소세포폐암 표적항암 치료에 대한 최신 Real-world Evidence 업데이트- RESET study
